English|简体中文|Site Map|Add to favorite
  • Home
  • About Us
  • Products
    • API and Related Substances
    • API Intermediates
      • Canagliflozin Intermediates
      • Empagliflozin Intermediates
      • Sofosbuvir Intermediates
      • Ledipasvir Intermediates
      • Efinaconazole intermediates
      • Ketorolac Intermediates
      • Formoterol Intermediates
    • Specialty/Fine Chemicals
      • Nucleoside
      • Fine Chemicals
  • Service & Technology
  • News
  • Careers
  • Contact Us
  • banner2
  • banner1
Categories

API and Related Substances

API Intermediates

  • Canagliflozin Intermediates
  • Empagliflozin Intermediates
  • Sofosbuvir Intermediates
  • Ledipasvir Intermediates
  • Efinaconazole intermediates
  • Ketorolac Intermediates
  • Formoterol Intermediates

Specialty/Fine Chemicals

  • Nucleoside
  • Fine Chemicals
Contact Us
Address: Room 305, Building 11, Jiangyue Road 999, Minhang District, Shanghai, China.
Tel: 86-021-26018649
Mobile: 17721318029
Fax: 86-021-26018649
QQ: 2899427924
Site: www.renshipharma.com
E-mail: info@renshipharma.com

News

  • Japan Clears First All-Oral Hepatitis C (Daclatasvir & Asunaprevir) Treatment Aug 1, 2014
  • Top 15 NIH-funded disease areas Jul 25, 2014
  • Healthy future for China’s drug market Jul 12, 2014
  • FDA Publishes Guidance on ANDA Submissions Jul 12, 2014
  • Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol Jul 12, 2014
  • When will Big Pharma get serious about antibiotic R&D? Jul 12, 2014
Home|About Us|Products|Service & Technology|News|Careers|Contact Us|Site Map
Copyright © 2010-2015 Renshi pharmatech Co. Ltd.  All Rights Reserved.